2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Elaine Soliven, 20230713000000

Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.

KEYNOTE-826: Sustained survival benefit with pembro + chemo in advanced cervical cancer

Elaine Soliven, 20230711000000

The addition of pembrolizumab immunotherapy to chemotherapy, either with or without bevacizumab, continues to confer survival benefit in patients with persistent, recurrent, or metastatic cervical cancer, regardless of their programmed death-ligand 1 (PD-L1) combined positive score (CPS), according to the updated results of the KEYNOTE-826 trial presented at ASCO 2023.

Vorasidenib may be chemo–RT-sparing in certain low-grade gliomas

Elvira Manzano, 20230710000000

The oral drug vorasidenib delays disease progression compared with placebo in patients with residual or recurrent grade 2 gliomas harbouring an isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutation in the phase III INDIGO trial.

CV health tool effectively promotes discussions during routine follow-up in cancer survivors

Audrey Abella, 20230706100000

A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.

Sacituzumab govitecan proven safe, effective in metastatic breast cancer

Stephen Padilla, 20230626120000

Treatment with sacituzumab govitecan (SG) demonstrates clinically meaningful overall survival (OS) over single-agent chemotherapy in patients with pretreated, endocrine-resistant, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), as confirmed by the final OS analysis from the TROPiCS-02 study, presented at ASCO 2023.

ZUMA-5: CAR T-cell therapy shows promise in R/R non-Hodgkin lymphoma

Nivolumab-AVD superior to brentuximab vedotin-AVD for advanced stage Hodgkin lymphoma

Stephen Padilla, 20230622120000

Treatment with nivolumab (N) plus doxorubicin, vinblastine, and dacarbazine (AVD) leads to improved progression-free survival (PFS) relative to brentuximab vedotin (BV) plus AVD in patients with advanced stage classic Hodgkin lymphoma (HL), according to the results of the SWOG S1826 study, which was presented at the recent ASCO 2023.

Erdafitinib prevails in bladder cancer with select FGFRalt

Audrey Abella, 20230622100000

The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

20230618080000

In the treatment of patients with colon cancer, neoadjuvant chemotherapy does not appear to yield better survival benefit than standard upfront surgery, according to the results of the phase III NeoCol trial presented at ASCO 2023.

Ribociclib plus endocrine therapy: A win for early breast cancer?

Audrey Abella, 20230616100000

In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.

Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK

Jairia Dela Cruz, 20230612140000

For patients with advanced nonsmall cell lung cance r (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.